NCT06747156View on ClinicalTrials.gov

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2027

Conditions
Autoimmune Diseases
Interventions
DRUG

ABO2203 Injection

Name of Active Ingredient: mRNA encoding CD19/CD3 T cell engager

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
collaborator

Abogen Life Sciences (Shanghai) Co., Ltd.

UNKNOWN

lead

Ruijin Hospital

OTHER